<DOC>
	<DOCNO>NCT01633580</DOCNO>
	<brief_summary>The purpose present study analyse corifollitropin alfa , agent prolong ovarian stimulation , administer day 4 clinically use instead day 2 onwards control ovarian hyperstimulation ( COH ) antagonist protocol .</brief_summary>
	<brief_title>D2 Versus D4 Corifollitropin Alfa GnRH Antagonists</brief_title>
	<detailed_description>Corifollitropin alfa new recombinant gonadotrophin sustain follicle-stimulating activity . It offer novel effective treatment option potential normal responder patient undergo ovarian stimulation GnRH antagonist co-treatment IVF vitro fertilisation result high ongoing pregnancy rate , equal achieve daily rFSH . Normally , medication start day 2 cycle . In present randomised trial , want evaluate whether agent clinically use start day 4 cycle .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<criteria>&lt; 36 year old day randomisation FSH &lt; 12 ( early follicular phase ) Normal ultrasound scan , i.e . presence ovary , without evidence abnormality within 6 month prior randomisation . Regular menstrual cycle 2135 day , presumed ovulatory . BMI ≤ 29 Weight &gt; 60 kg &lt; 3 previous trial ICSI Randomisation outpatient clinic ≥ 36 year old day randomisation Endometriosis ≥ grade 3 PCOS Poor responder ( development &lt; 4 follicle previous IVF/ICSI cycle ) Endocrine metabolic abnormality ( pituitary , adrenal , pancreas , liver kidney )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>ICSI</keyword>
	<keyword>GnRH antagonist</keyword>
	<keyword>corifollitropin alfa</keyword>
</DOC>